Om

AIM ImmunoTech Inc. is a biotechnology company focused on developing immuno-modulating therapeutics for cancer, viral diseases, and immune-related disorders. Its current portfolio centers on Ampligen, an investigational double-stranded RNA therapy being evaluated in clinical studies for oncology and selected viral and immune conditions, and Alferon N Injection, a natural-source interferon product used for specific approved indications. The company works across preclinical and clinical research, with an emphasis on immune system activation, antiviral defense, and combination approaches for difficult-to-treat diseases. AIM ImmunoTech serves the biopharmaceutical sector by advancing specialized therapies that target areas with limited treatment options, making it a recognized participant in immunotherapy and antiviral drug development.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I AIM IMMUNOTECH MED ENDAVU: Køb AIM ImmunoTech ($AIM) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i AIM ImmunoTech, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.